Recent advances in amyotrophic lateral sclerosis research

Current Neurology and Neuroscience Reports

Volumn 3, Issue 1, 2003, Pages 70-77

  Przedborski, Serge ^a   Mitsumoto, Hiroshi ^a   Rowland, Lewis P ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; BOTULINUM TOXIN; CREATINE; GABAPENTIN; PROTEINASE INHIBITOR; RILUZOLE; RNA DIRECTED DNA POLYMERASE INHIBITOR; SUPEROXIDE DISMUTASE; COPPER ZINC SUPEROXIDE DISMUTASE;

ALLELE; AMYOTROPHIC LATERAL SCLEROSIS; APOPTOSIS; BREATHING MUSCLE; CELL DEATH; CLINICAL TRIAL; CREUTZFELDT JAKOB DISEASE; GENE EXPRESSION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENETIC SUSCEPTIBILITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN T CELL LEUKEMIA VIRUS 1; HYPERSALIVATION; LUNG FUNCTION; MOLECULAR MECHANICS; NONHUMAN; PALLIATIVE THERAPY; PERCUTANEOUS ENDOSCOPIC GASTROSTOMY; POSITIVE END EXPIRATORY PRESSURE; QUALITY OF LIFE; RETROVIRUS INFECTION; REVIEW; STRIDOR; TRISMUS; VITAL CAPACITY; ANIMAL; DISEASE MODEL; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MOTONEURON; MOUSE; MUTATION; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; VIROLOGY;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMALS; APOPTOSIS; CLINICAL TRIALS; DISEASE MODELS, ANIMAL; HIV INFECTIONS; HIV-1; HUMANS; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MUTATION; SUPEROXIDE DISMUTASE;

EID: 0141610941     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-003-0041-x     Document Type: Review

References (93)

1. Miller RG, Rosenberg JA, Gelinas DF, et al.: Practice parameter: the care of the patient with amyotrophic lateral sclerosis (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology: ALS Practice Parameters Task Force. Neurology 1999, 52:1311-1323.
2. Bradley WG, Anderson F, Bromberg M, et al., for the ALS CARE Study Group: Current management of ALS: comparison of the ALS CARE Database and the AAN Practice Parameter. The American Academy of Neurology. Neurology 2001, 57:500-504.
3. Newsom-Davis IC, Lyall RA, Leigh PN, Moxham J, Goldstein LH: The effect of non-invasive positive pressure ventilation (NIPPV) on cognitive function in amyotrophic lateral sclerosis (ALS): a prospective study. J Neurol Neurosurg Psychiatry 2001, 71:482-487.
4. Lyall RA, Donaldson N, Fleming T, et al.: A prospective study of quality of life in ALS patients treated with noninvasive ventilation. Neurology 2001, 57:153-156.
5. Bourke SC, Shaw PJ, Gibson GJ: Respiratory function vs sleep-disordered breathing as predictors of QOL in ALS. Neurology 2001, 57:2040-2044.
6. Bach JR: Amyotrophic lateral sclerosis: prolongation of life by noninvasive respiratory aids. Chest 2002, 122:92-98.
7. Aboussouan LS, Khan SU, Banerjee M, Arroliga AC, Mitsumoto H: Objective measures of the efficacy of noninvasive positive-pressure ventilation in amyotrophic lateral sclerosis. Muscle Nerve 2001, 24:403-409.
8. Lyall RA, Donaldson N, Polkey MI, Leigh PN, Moxham J: Respiratory muscle strength and ventilatory failure in amyotrophic lateral sclerosis. Brain 2001, 124:2000-2013.
9. Sivak ED, Shefner JM, Mitsumoto H, Taft JM: The use of non-invasive positive pressure ventilation (NIPPV) in ALS patients. A need for improved determination of intervention timing. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2:139-145.
10. Albert SM, Murphy PL, Del Bene M, Rowland LP, Mitsumoto H: Incidence and predictors of PEG placement in ALS/MND. J Neurol Sci 2001, 191:115-119.
11. Desport JC, Preux PM, Magy L, et al.: Factors correlated with hypermetabolism in patients with amyotrophic lateral sclerosis. Am J Clin Nutr 2001, 74:328-334.
12. Kasarskis EJ, Berryman S, Vanderleest JG, Schneider AR, McClain CJ: Nutritional status of patients with amyotrophic lateral sclerosis: relation to the proximity of death. Am J Clin Nutr 1996, 63:130-137.
13. Boitano LJ, Jordan T, Benditt JO: Noninvasive ventilation allows gastrostomy tube placement in patients with advanced ALS. Neurology 2001, 56:413-414.
14. Gregory S, Siderowf A, Golaszewski AL, McCluskey L: Gastrostomy insertion in ALS patients with low vital capacity: respiratory support and survival. Neurology 2002, 58:485-487.
15. Andersen PM, Gronberg H, Franzen L, Funegard U: External radiation of the parotid glands significantly reduces drooling in patients with motor neurone disease with bulbar paresis. J Neurol Sci 2001, 191:111-114.
16. Geiss R, Naumann M, Werner E, et al.: Injections of botulinum toxin A into the salivary glands improves sialorrhea in amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry 2000, 69:121-123.
17. Tan EK, Lo YL, Seah A, Auchus AP: Recurrent jaw dislocation after botulinum toxin treatment for sialorrhea in amyotrophic lateral sclerosis. J Neurol Sci 2001, 190:95-97.
18. Martin J, Turnbull J: Lasting impact in families after death from ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2:181-187.
19. Debove C, Zeisser P, Salzman PM, Powe LK, Truffinet P: The Rilutek (riluzole) Global Early Access Programme: an open-label safety evaluation in the treatment of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2:153-158.
20. Lacomblez L, Bensimon G, Leigh PN, et al.: Long-term safety of riluzole in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002, 3:23-29.
21. Bensimon G, Lacomblez L, Delumeau JC, et al.: A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol 2002, 249:609-615.
22. Miller RG., Mitchell JD, Lyon M, Moore DH: Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) (Cochrane Review). Cochrane Database Syst Rev 2002, 2:CD001447.
23. Desnuelle C, Dib M, Garrel C, Favier A: A double-blind, placebo-controlled randomized clinical trial of alpha-tocopherol (vitamin E) in the treatment of amyotrophic lateral sclerosis. ALS riluzole-tocopherol Study Group. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2:9-18.
24. Drory VE, Gross D: No effect of creatine on respiratory distress in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002, 3:43-46.
25. Mazzini L, Balzarini C, Colombo R, et al.: Effects of creatine supplementation on exercise performance and muscular strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci 2001, 191:139-144.
26. Rowland LP, Shneider NA: Amyotrophic lateral sclerosis. N Engl J Med 2001, 344:1688-1700.
27. Wasner M, Klier H, Borasio GD: The use of alternative medicine by patients with amyotrophic lateral sclerosis. J Neurol Sci 2001, 191:151-154.
28. Mandler RN, Anderson FA Jr, Miller RG, et al., for the ALS C.A.R.E. Study Group: The ALS Patient Care Database: insights into end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2:203-208.
29. Veldink JH, Wokke JH, van der Wal G, Vianney de Jong JM, van den Berg LH: Euthanasia and physician -assisted suicide among patients with amyotrophic lateral sclerosis in the Netherlands. N Engl J Med 2002, 346:1638-1644.
30. Ganzini L, Block S: Physician-assisted death - a last resort? N Engl J Med 2002, 346:1663-1665.
31. Berger MM, Kopp N, Vital C, et al.: Detection and cellular localization of enterovirus RNA sequences in spinal cord of patients with ALS. Neurology 2000, 54:20-25.
32. Giraud P, Beaulieux F, Ono S, et al.: Detection of enteroviral sequences from frozen spinal cord samples of Japanese ALS patients. Neurology 2001, 56:1777-1778.
33. Walker MP, Schlaberg R, Hays AP, Bowser R, Lipkin WI: Absence of echovirus sequences in brain and spinal cord of amyotrophic lateral sclerosis patients. Ann Neurol 2001, 49:249-253.
34. MacCowan DJ, Scelsa SN, Waldron M: An ALS-like syndrome with new HIV infection and complete response to antiretroviral therapy. Neurology 2001, 57:1094-1097.
35. Moulignier A, Moulonguet A, Pialoux G, Rozenbaum W: Reversible ALS-like disorder in HIV infection. Neurology 2001, 57:995-1001.
36. Nishio M, Koizumi K, Moriwaka F, Koike T, Sawada K: Reversal of HIV-associated motor neuron syndrome after highly active antiretroviral therapy. J Neurol 2000, 248:233-234.
37. Zoccolella S, Carbonara S, Minerva D, et al.: A case of concomitant amyotrophic lateral sclerosis and HIV infection. Eur J Neurol 2002, 9:180-182.
38. Sastre-Garriga J, Tintoré M, Raguer N, et al.: Lower motor neuron disease in a HIV-2 infected woman. J Neurol 2000, 247:718-719.
39. Goudreau G, Carpenter S, Beaulieu N, Jolicoeur P: Vacuolar myelopathy in transgenic mice expressing human immuno-deficiency virus type 1 proteins under the regulation of the myelin basic protein gene promoter. Nat Med 1996, 2:655-661.
40. Thomas FP, Chalk C, Lalonde R, Robitaille Y, Jolicoeur P: Expression of human immunodeficiency virus type 1 in the nervous system of transgenic mice leads to neurological disease. J Virol 1994, 68:7099-7107.
41. Andrews WD, Tuke PW, Al-Chalabi A, et al.: Detection of reverse transcriptase activity in the serum of patients with motor neuron disease. J Med Virol 2000, 61:527-532.
42. Hand CK, Rouleau GA: Familial amyotrophic lateral sclerosis. Muscle Nerve 2002, 25:135-159.
43. Orrell RW, Figlewicz D: Clinical implications of the genetics of ALS and other motor neuron diseases. Neurology 2001, 57:9-17.
44. Shaw PJ: Genetic inroads in familial ALS. Nat Genet 2001, 29: 103-104.
45. Andersen PM: Genetics of sporadic ALS. Amyotroph Lateral Scler Other Motor Neuron Disord 2001, 2(suppl 1):S37-S41.
46. Rowland LP: What's in a name? Amyotrophic lateral sclerosis, motor neuron disease, and allelic heterogeneity. Ann Neurol 1998, 43:691-694.
47. Hadano S, Hand CK, Osuga H, et al.: A gene encoding a putative GTPase regulator is mutated in familial amyotrophic lateral sclerosis 2. Nat Genet 2001, 29:166-173.
48. Yang Y, Hentati A, et al.: The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat Genet 2001, 29:160-165.
49. Rowland LP: Molecular basis of genetic heterogeneity: role of the clinical neurologist. J Child Neurol 1998, 13:122-132.
50. Chance PF, Rabin BA, Ryan SG, et al.: Linkage to the gene for autosomal dominant form of juvenile amyntrophic lateral sclerosis to chromosome 9q34. Am J Hum Genet 1998, 62:633-640.
51. De Jonghe P, Auer-Grumbach M, Irobi J, et al.: Autosomal dominant juvenile amyotrophic lateral sclerosis and distal hereditary motor neuronopathy with pyramidal tract signs: synonyms for the same disorder? Brain 2002, 125:1320-1325.
52. Online Mendelian Inheritance in Man. http://www.ncbi.nlm.nih.gov/htbin-post/Omim/getmin. Accessed September 7, 2002.
53. Hentati A, Oualchi K, Pericak-Vance MA, et al.: Linkage of a commoner form of recessive amyntrophic lateral sclerosis maps to chromosome 15q15-q22 markers. Neurogenetics 1998, 2:55-60.
54. Hand CK, Khoris J, Salachas F, et al.: A novel locus for familial amyotrophic lateral sclerosis, on chromosome 18q. Am J Hum Genet 2002, 70:251-256.
55. Hosler BA, Siddique T, Sapp PC, et al.: Linkage of familial amyotrophic lateral sclerosis with frontotemporal dementia to chromosome 9q21-q22. JAMA 2000, 284:1664-1669.
56. Comi GP, Bordoni A, Salani S, et al.: Cytochrome c oxidase subunit 1 microdeletion in a patient with motor neuron disease. Ann Neurol 1998, 43:110-116.
57. Corcia P, Mayeux-Portas V, Khoris J, et al.: Amyotrophic lateral sclerosis. Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann Neurol 2002, 51:243-246.
58. Poorkaj P, Tsuang D, Wijsman E, et al.: TAU as a susceptibility gene for amyotrophic lateral sclerosis-parkinsonism dementia complex of Guam. Arch Neurol 2001, 58:1871-1878.
59. Giess R, Holtmann B, Braga M, et al.: Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: potential impact of CNTF as a candidate modifier gene. Am J Hum Genet 2002, 70:1277-1286.
60. Drory VE, Birnbaum M, Korczyn AD, Chapman J: Association of APOE epsilon4 allele with survival in amyotrophic laterals sclerosis. J Neurol Sci 2001, 190:17-20.
61. Lacomblez L, Doppler V, Beucler I, et al.: APOE: a potential marker of disease progression in ALS. Neurology 2002, 58:1112-1114.
62. Mui S, Rebeck CW, McKenna-Yasek D, Hyman BT, Brown RH Jr: Apolipoprotein E epsilon 4 allele is not associated with earlier age at onset in amyotrophic lateral sclerosis. Ann Neurol 1995, 38:460-463.
63. Goizet C, Catari B, Tison F , et al.: Progressive bulbospinal amyotrophy in triple A syndrome with AAAS gene mutation. Neurology, 2002, 58:962-965.
64. Oosthuyse B, Moons L, Storkebaum E, et al.: Deletion of the hypoxia-response element in the vascular endothelial growth factor promoter causes motor neuron degeneration. Nature Genet 2001, 28:131-138.
65. Gurney ME, Pu H, Chiu AY, et al.: Motor neuron degeneration in mice that express a human Cu, Zn superoxide dismutase mutation. Science 1994, 264:1772-1775.
66. Wong PC, Pardo CA, Borchelt DR, et al.: An adverse property of a familial ALS-linked SOD1 mutation causes motor neuron disease characterized by vacuolar degeneration of mitochondria. Neuron 1995, 14:1105-1116.
67. Bruijn LI, Becher MW, Lee MK, et al.: ALS-linked SOD1 mutant G85R mediated damage to astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. Neuron 1997, 18:327-338.
68. Nagai M, Aoki M, Miyoshi I, et al.: Rats expressing human cytosolic copper-zinc superoxide dismutase transgenes with amyotrophic lateral sclerosis: associated mutations develop motor neuron disease. J Neurosci 2001, 21:9246-9254.
69. Chiu AY, Zhai P, Dal Canto MC, et al.: Age-dependent penetrance of disease in a transgenic mouse model of familial amyotrophic lateral sclerosis. Mol Cell Neurosci 1995, 6:349-362.
70. Dal Canto MC, Gurney ME: Neuropathological changes in two lines of mice carrying a transgene for mutant human Cu,Zn SOD, and in mice overexpressing wild type human SOD: a model of familial amyotrophic lateral sclerosis (FALS). Brain Res 1995, 676:25-40.
71. Almer G, Vukosavic S, Romero N, Przedborski S: Inducible nitric oxide synthase upregulation in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999, 72:2415-2425.
72. Tu PH, Raju P, Robinson KA, et al.: Transgenic mice carrying a human mutant superoxide dismutase transgene develop neuronal cytoskeletal pathology resembling human amyotrophic lateral sclerosis lesions. Proc Natl Acad Sci U S A 1996, 93:3155-3160.
73. Cleveland DW, Rothstein JD: From Charcot to Lou Gehrig: deciphering selective motor neuron death in ALS. Nat Rev Neurosci 2001, 2:806-819.
74. Beckman JS, Carson M, Smith CD, Koppenol WH: ALS, SOD and peroxynitrite. Nature 1993, 364:584.
75. Wiedau-Pazos M, Coto JJ, Rabizadeh S, et al.: Altered reactivity of superoxide dismutase in familial amyotrophic lateral sclerosis. Science 1996, 271:515-518.
76. Crow JP, Sampson JB, Zhuang YX, Thompson JA, Beckman JS: Decreased zinc affinity of amyotrophic lateral sclerosis-associated superoxide dismutase mutants leads to enhanced catalysis of tyrosine nitration by peroxynitrite. J Neurochem 1997, 69:1936-1944.
77. Estevez AG, Crow JP, Sampson JB, et al.: Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase. Science 1999, 286:2498-2500.
78. Bruijn LI, Houseweart MK, Kato S, et al.: Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 1998, 281:1851-1854.
79. Durham HD, Roy J, Dong L, Figlewicz DA: Aggregation of mutant Cu/Zn superoxide dismutase proteins in a culture model of ALS. J Neuropathol Exp Neurol 1997, 56:523-530.
80. Johnson WG: Late-onset neurodegenerative diseases - the role of protein insolubility. J Anat 2000, 196(Pt 4):609-616.
81. Rabizadeh S, Gralla EB, Borchelt DR, et al.: Mutations associated with amyotrophic lateral sclerosis convert superoxide dismutase from an antiapoptotic gene to a proapoptotic gene: studies in yeast and neural cells. Proc Natl Acad Sci U S A 1995, 92:3024-3028.
82. Ghadge GD, Lee JP, Bindokas VP, et al.: Mutant superoxide dismutase-1-linked familial amyotrophic lateral sclerosis: molecular mechanisms of neuronal death and protection. J Neurosci 1997, 17:8756-8766.
83. Mena MA, Khan U, Togasaki DM, et al.: Effects of wild-type and mutated copper/zinc superoxide dismutase on neuronal survival and L-DOPA-induced toxicity in postnatal midbrain culture. J Neurochem 1997, 69:21-33.
84. Roy N, Mahadevan MS, McLean M, et al.: The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 1995, 80:167-178.
85. Vukosavic S, Dubois-Dauphin M, Romero N, Przedborski S: Bax and Bcl-2 interaction in a transgenic mouse model of familial amyotrophic lateral sclerosis. J Neurochem 1999, 73:2460-2468.
86. Guégan C, Vila M, Rosoklija G, Hays AP, Przedborski S: Recruitment of the mitochondrial-dependent apoptotic pathway in amyotrophic lateral sclerosis. J Neurosci 2001, 21:6569-6576.
87. Pasinelli P, Borchelt DR, Houseweart MK, Cleveland DW, Brown RH: Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc Natl Acad Set U S A 1998, 95:15763-15768.
88. Friedlander RM, Brown RH, Gagliardini V, Wang J, Yuan J: Inhibition of ICE slows ALS in mice. Nature 1997, 388:31.
89. Vukosavic S, Stefanis L, Jackson-Lewis V, et al.: Delaying caspase activation by Bcl-2: a clue to disease retardation in a transgenic mouse model of amyotrophic lateral sclerosis. J Neurosci 2000, 20:9119-9125.
90. Li M, Ona VO, Guegan C, et al.: Functional role of caspase-1 and caspase-3 in an ALS transgenic mouse model. Science 2000, 288:335-339.
91. Kuida K, Haydar TF, Kuan CY, et al.: Reduced apoptosis and cytochrome c-mediated caspase activation in mice lacking caspase 9. Cell 1998, 94:325-337.
92. Martin LJ: Neuronal death in amyotrophic lateral sclerosis is apoptosis: possible contribution of a programmed cell death mechanism. J Neuropathol Exp Neurol 1999, 58:459-471.
93. Kostic V, Jackson-Lewis V, De Bilbao F, Dubois-Dauphin M, Przedborski S: Bcl-2: prolonging life in a transgenic mouse model of familial amyotrophic lateral sclerosis. Science 1997, 277:559-562.